UK product information advises that patients should: Recognise symptoms of pancreatitis (severe, persistent abdominal pain radiating to the back, nausea, vomiting) Seek immediate medical attention if these symptoms develop Discontinue the medicine if pancreatitis is suspected Not restart the GLP-1 medicine if pancreatitis is confirmed Patients should also be aware of an increased risk of gallbladder disease (gallstones, cholecystitis) with GLP-1 medicines, which can present with similar abdominal symptoms and requires prompt medical attention
Conversely, downregulated DEGs were enriched in BP categories related to synapse organization, extracellular matrix organization, and extracellular structure organization
Ice the area for 5-10 minutes after injection if you tend to bruise easily
Please note that our program is not suitable for patients who are insulin-dependent diabetic or have a tendency to develop diabetic ketoacidosis
Residual peptide solution, used consumables, and cartridge packaging should be treated as laboratory chemical waste and disposed of in compliance with institutional and local waste management protocols
